Toll-like receptor

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

Retrieved on: 
Dienstag, Januar 12, 2021
Branches of biology, Medical specialties, Life sciences, Immunology, Interleukin-1 receptor associated kinase, Signal transduction, IRAK4, Toll-like receptor, Inflammation, Biopharmaceutical

IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).

Key Points: 
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).
  • Kymera is also developing a new generation of tissue-selective or -restricted degrader medicines with the goal of drugging an entirely new set of protein targets.
  • The Companys goal is to become a fully integrated biopharmaceutical company with a pipeline of novel medicines targeting disease-causing proteins that were previously intractable.
  • Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets.

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Retrieved on: 
Mittwoch, Dezember 30, 2020
Branches of biology, Biology, Pharmacodynamics, Signal transduction, Cell signaling, TLR7, Toll-like receptor, Resiquimod, Agonist, Receptor

TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8.

Key Points: 
  • TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8.
  • TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two.
  • When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner.
  • Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group.

Primmune Therapeutics Announces $27.4 Million Series A Financing

Retrieved on: 
Dienstag, Oktober 27, 2020
Oncology, Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, TLR7, Toll-like receptor, Immunotherapy

Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists as therapeutic-adjuvants for acute viral diseases and cancer.

Key Points: 
  • Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists as therapeutic-adjuvants for acute viral diseases and cancer.
  • The financing was co-led by CAM Capital and Polaris Partners and included new investors Samsara BioCapital and Oberland Capital as well as existing investors McDermott, BioRock Ventures and BioBrit.
  • The Series A financing included the conversion of $7.4 million in convertible seed capital securities.
  • Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

Retrieved on: 
Montag, Oktober 26, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Immunology, Eritoran, Immunosuppressants, TLR4, Pharmaceutical industry, Toll-like receptor, Eisai, Pharma, REMAP-CAP, Otezla® (apremilast), Eritoran (E5564), Global Coalition for Adaptive Research (GCAR), UPMC (University of Pittsburgh Medical Center), Amgen, Eisai Co., Ltd.

This trial is a multicenter, randomized platform study, with treatments tested within groupings or domains based on pathway or mechanism of action.

Key Points: 
  • This trial is a multicenter, randomized platform study, with treatments tested within groupings or domains based on pathway or mechanism of action.
  • Eritoran is Eisais in-house discovered and developed investigational TLR4 (Toll-Like Receptor 4) antagonist created with natural product organic synthesis technology.
  • Global Coalition for Adaptive Research (GCAR) is the US Sponsor of REMAP-COVID and is guiding efforts to facilitate the inclusion of multiple pharma partners in REMAP-COVID globally.
  • Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.

Primmune Therapeutics Announces the Selection of PRTX007 as Its Clinical Development Candidate for COVID-19 and Oncology Indications

Retrieved on: 
Dienstag, März 31, 2020
Medical specialties, Branches of biology, Medicine, Immunology, Cytokines, TLR7, Immune system, Inflammatory cytokine, Severe acute respiratory syndrome-related coronavirus, Toll-like receptor, Tumor necrosis factor alpha, Cytokine

SAN DIEGO, March 31, 2020 /PRNewswire/ -- Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications.

Key Points: 
  • SAN DIEGO, March 31, 2020 /PRNewswire/ -- Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications.
  • "PRTX007 is an oral small molecule that specifically activates toll-like receptor 7 ("TLR7") which drives the innate immune system's primary response to viral infections," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics.
  • "PRTX007 was derived from Primmune's extensive TLR7 agonist discovery program and has demonstrated sustained dose-dependent innate immune induction in vivo without the production of inflammatory cytokines, such as IL-6 or TNF alpha.
  • "Since PRTX007 stimulates your natural antiviral innate immune response, we believe it has potential utility as a prophylaxis, first-line defense against SARS-CoV-2, SARS-CoV-2 mutants, and future novel pathogens."

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Retrieved on: 
Dienstag, März 24, 2020
Other Health, Research, Pharmaceutical, Infectious diseases, Other Manufacturing, Genetics, Clinical trials, Science, Biotechnology, FDA, Manufacturing, Health, Medical specialties, Medicine, Branches of biology, Vaccines, Vaccination, Cancer vaccines, Adjuvants, TLR9, Hepatitis B vaccine, Vaccine, Immunologic adjuvant, Toll-like receptor, the Novel Coronavirus SARS-CoV-2 (and COVID-19 Disease), COVID-19 S-Trimer Vaccine, Clover Biopharmaceuticals, Dynavax

Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.

Key Points: 
  • Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.
  • Dynavax is providing technical expertise and the companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.
  • CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
  • Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.

Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

Retrieved on: 
Montag, März 2, 2020
Branches of biology, Medicine, Medical specialties, TLR7, Immunology, Toll-like receptor, Immunotherapy, Immune system

Primmune is being led by an experienced and dedicated team, which includes:

Key Points: 
  • Primmune is being led by an experienced and dedicated team, which includes:
    Mr. McDermott is Chairman, President & CEO of Primmune.
  • Most recently, Mr. McDermott was President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc.
  • Before Primmune, Mr. Rangel was President & CEO and Co-founder of Evince Biosciences, a precursor to Primmune Therapeutics.
  • Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

Primmune Therapeutics Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Mittwoch, November 6, 2019
Medical specialties, Medicine, Branches of biology, Immunology, TLR7, Cancer immunotherapy, Toll-like receptor, Immune system, Dendritic cell, Immunotherapy

SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD.

Key Points: 
  • SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD.
  • PRX034 is a novel orally bioavailable small molecule toll-like receptor 7 (TLR7) agonist that activates innate immunity by systemically targeting plasmic cytoid dendritic cells in vivo.
  • PRX034 was derived from Primmune's lead series of novel TLR7 agonists and demonstrates the potential of these compounds to improve response rates and treatment durability of adaptive immune therapies.
  • Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Primmune Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019

Retrieved on: 
Montag, April 1, 2019
TLR7, Immune system, Toll-like receptor, Adaptive immune system

SAN DIEGO, April 1, 2019 /PRNewswire/ -- Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA.

Key Points: 
  • SAN DIEGO, April 1, 2019 /PRNewswire/ -- Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA.
  • The research demonstrates the potential of our oral TLR7 agonists to improve response rates and treatment durability.
  • "There is a very strong rationale for combining agents that activate innate immunity, like TLR7 agonists, with drugs that engage adaptive immunity, like checkpoint inhibitors.
  • This approach has the potential to address patients who inadequately respond to approved treatments," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics.

Gastrointestinal Diseases Drug Development Pipeline Review, 2018: Gastroenteritis, Enterocolitis, Gastritis and Peritonitis - ResearchAndMarkets.com

Retrieved on: 
Freitag, Januar 11, 2019
Health, Pharmaceutical, Biological nomenclature, Gastro-, Prefixes, Gastrointestinal tract, Toll-like receptor, Health, Biology, Medicine

The "Gastrointestinal Diseases Drug Development Pipeline Review 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Diseases Drug Development Pipeline Review 2018" report has been added to ResearchAndMarkets.com's offering.
  • Gastrointestinal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for gastrointestinal diseases.
  • It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.
  • Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins.